Safety and Efficacy of a DNA Oligonucleotide Therapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
| Autor: | Wael A. Harb, Barbara Klencke, Prapti A. Patel, Kelly McCaul, Ayad Al-Katib, Nehal Lakhani, Jason R. Westin, Dipti Patel-Donnelly, Michael B. Maris, Carolina Escobar, Caron A. Jacobson |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Adult
Oncology Cancer Research medicine.medical_specialty medicine.medical_treatment Population Oligonucleotides Refractory Recurrence Internal medicine Humans Medicine Refractory Diffuse Large B-Cell Lymphoma education Adverse effect Aged Aged 80 and over Chemotherapy education.field_of_study Performance status business.industry DNA Hematology Middle Aged Interim analysis medicine.disease Treatment Outcome Lymphoma Large B-Cell Diffuse business Diffuse large B-cell lymphoma |
| Zdroj: | Clinical Lymphoma Myeloma and Leukemia. 22:52-59 |
| ISSN: | 2152-2650 |
| DOI: | 10.1016/j.clml.2021.07.020 |
| Popis: | Background PNT2258 is a liposomal formulation that encapsulates multiple copies of PNT100, a native, chemically unmodified, 24-base DNA oligonucleotide designed to target the regulatory region upstream of the B-cell lymphoma 2 (BCL2) gene. Methods This phase II, multicenter, single-arm, open-label, 2-stage design study investigated the single-agent activity of PNT2258 in patients with relapsed/refractory DLBCL. Initially, patients had to have a performance status (PS) of ≤2 and prior exposure to CD20-targeted therapy, an alkylating agent, and a steroid with no upper limit. Criteria were modified to PS of 0 or 1 and at least 1 to ≤3 prior therapies (identified as the target population) after observing an initially high frequency of rapid disease progression in patients with extensive prior therapies or poor PS. Results The study was stopped early following an interim analysis, despite surpassing the protocol predetermined futility boundary, because the ORR was below the expectations of response in an evolving DLBCL treatment landscape. The final analysis included all 45 enrolled patients and demonstrated an ORR of 11%. In the response evaluable subset (n = 26), defined as patients in the target population with exposure to ≥8 doses of PNT2258 within the first 35 days and evaluable baseline/post-baseline scans, the ORR was 19%. The most common adverse events were fatigue (44%), nausea (42%), diarrhea (40%), pyrexia (36%), anemia (32%), and vomiting (27%). Conclusions PNT2258 was well-tolerated in a chemotherapy refractory DLBCL population. Despite demonstration of single-agent activity, ORR was lower than acceptable for further new therapy development. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect